Exciting News from Repligen Corporation
WALTHAM, Mass. — Repligen Corporation (NASDAQ:RGEN), a leader in life sciences focused on advancing bioprocessing technologies, has just announced its participation in several key investor conferences. These events present significant opportunities for the company to showcase its expertise and innovations in the biopharmaceutical sector.
Details of the Upcoming Conferences
Repligen will feature at three high-profile investor events:
1. UBS Global Healthcare Conference
The UBS Global Healthcare Conference is set to take place from November 11-14, where Jason Garland, the Chief Financial Officer of Repligen, will engage in an analyst-led discussion on Thursday, November 14. This session promises insights into the company's strategic vision and financial health.
2. Stifel Healthcare Conference
Following UBS, Repligen will present at the Stifel Healthcare Conference on November 18-19, in New York City. Both CEO Olivier Loeillot and CFO Jason Garland will participate in an analyst-led discussion that is poised to deepen investor understanding of Repligen's market positioning and growth potential.
3. Stephens Annual Investment Conference
Rounding out this series of presentations is the Stephens Annual Investment Conference from November 19-21 in Nashville. Here, the executive team will once again address investors and analysts on November 20, highlighting advancements in their bioprocessing technologies and future plans.
Accessing Live Webcasts
For those unable to attend in person, the good news is that Repligen will provide live webcasts of these crucial sessions, which can be accessed through the company’s Investor Relations website. Each presentation will also be available for replay for a limited time, ensuring that stakeholders can stay informed regardless of their availability.
About Repligen Corporation
Repligen Corporation stands at the forefront of bioprocessing innovation, creating solutions that enhance the manufacturing of biological drugs. The company’s mantra of “inspiring advances in bioprocessing” underscores their commitment to supporting biopharmaceutical developers and contract manufacturing organizations globally. Key focus areas for Repligen include filtration and fluid management, chromatography, process analytics, and protein production. With corporate headquarters in Waltham, Massachusetts, the company boasts multiple manufacturing facilities across the U.S. and in Europe, including locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden. To discover more about Repligen’s groundbreaking work, visit their website.
Contact Information
If you have inquiries regarding Repligen, please reach out to Sondra S. Newman, the Global Head of Investor Relations. You can contact her at (781) 419-1881 or via email at investors@repligen.com.
Frequently Asked Questions
What is the significance of the upcoming conferences for Repligen?
The conferences provide a platform for Repligen to present its latest innovations and strategies directly to investors and analysts, fostering deeper engagement and understanding.
Who will represent Repligen at these conferences?
Jason Garland, Chief Financial Officer, and Olivier Loeillot, Chief Executive Officer, are key representatives attending and discussing the company’s initiatives.
How can I watch the Repligen presentations if I cannot attend?
You can watch the live webcasts of the presentations through Repligen’s Investor Relations website, with replays available for a short period afterward.
What is Repligen Corporation known for?
Repligen is known for developing innovative bioprocessing technologies that streamline the manufacturing of biological drugs, focusing on areas like filtration and chromatography.
How can I contact Repligen's investor relations?
You can reach out to Sondra S. Newman, the Global Head of Investor Relations, at (781) 419-1881 or via email at investors@repligen.com.
